![]()
|
|
||||||||
J Biol Chem, Vol. 275, Issue 3, 2205-2210, January 21, 2000
From the Shriners Hospital for Children and the
§ Department of Biochemistry and Molecular Biology, Oregon
Health Sciences University, Portland, Oregon 97201
Fibrillins are the major constituents of
extracellular microfibrils. How fibrillin molecules assemble into
microfibrils is not known. Sequential extractions and pulse-chase
labeling of organ cultures of embryonic chick aortae revealed rapid
formation of disulfide-cross-linked aggregates containing fibrillin-1.
These results demonstrated that intermolecular disulfide bond formation is an initial step in the assembly process. To identify free cysteine residues available for intermolecular cross-linking, small recombinant peptides of fibrillin-1 harboring candidate cysteine residues were
analyzed. Results revealed that the first four cysteine residues in the
unique N terminus form intramolecular disulfide bonds. One cysteine
residue (Cys204) in the first hybrid domain of
fibrillin-1 was found to occur as a free thiol and is therefore a good
candidate for intermolecular disulfide bonding in initial steps of the
assembly process. Furthermore, evidence indicated that the comparable
cysteine residue in fibrillin-2 (Cys233) also occurs as a
free thiol. These free cysteine residues in fibrillins are readily
available for intermolecular disulfide bond formation, as determined by
reaction with Ellman's reagent. In addition to these major results,
the cleavage site of the fibrillin-1 signal peptide and the N-terminal
sequence of monomeric authentic fibrillin-1 from conditioned fibroblast
medium were determined.
Fibrillins are ubiquitous extracellular matrix macromolecules that
contribute to the structure of fibrous elements called "microfibrils" (1, 2). Single microfibrils can be extracted from
connective tissues following digestion of the tissue with crude
collagenase (3). However, microfibrils are difficult to solubilize into
their molecular components, because they are heavily cross-linked.
Therefore, our current understanding of how single molecules of
fibrillin are organized in microfibril polymers is based primarily upon
immunolocalization studies of microfibrils, using monoclonal antibodies
specific for mapped regions in the fibrillin-1 molecule (4). According
to this model, single molecules of fibrillin, which are extended
molecules of ~150 nm in length (5), may be arranged periodically in a parallel unstaggered (4) or a parallel staggered (6) orientation along
the length of the microfibril.
Initial investigations suggested that microfibrils are stabilized by
disulfide bonds, because extraction of tissues with disulfide-bond reducing agents resulted in loss of the ultrastructural features of
microfibrils (7). Fibrillin was first characterized as a cysteine-rich
monomeric molecule secreted into the medium by fibroblasts in culture
(1, 5). Cloning and sequencing of fibrillin demonstrated that most of
the fibrillin molecule is composed of cysteine-rich domains (8-10),
which are predicted to fold independently. The domain structure of
fibrillin is depicted in Fig. 1. There
are 47 epidermal growth factor-like domains, seven
"8-cysteine"-containing domains, and two "hybrid" domains (9).
If each of these domains is stabilized by intrachain disulfide bonds,
as predicted (4, 6, 11), then cysteine residues present in the N
terminus (four residues), the C terminus (two residues), or in the
first hybrid domain (nine residues) may be free to participate in the formation of intermolecular disulfide bonds.
These investigations were carried out in order to obtain biochemical
evidence for intermolecular disulfide bond formation by fibrillin and
to determine potential free cysteine residues in the N terminus and in
the first hybrid domain. Recombinant polypeptides of fibrillin utilized
for these studies are depicted in Fig. 1.
More than 200 individual mutations in FBN1 are known to result in the
Marfan syndrome, an autosomal dominant heritable disorder of connective
tissue (12, 13). A dominant negative effect of the mutant fibrillin-1
on the structure or stability of microfibrils is thought to cause the
skeletal, cardiovascular, and ocular symptoms of the disease. Central
to these discussions are issues related to the effect of mutant
fibrillin-1 molecules on assembly of microfibrils. Are mutant
fibrillin-1 molecules incorporated into microfibrils, where they may
destabilize the microfibrils by rendering them more susceptible to
proteolytic attack (14, 15)? Alternatively, do mutant molecules disrupt
microfibril assembly, resulting in short or fragmented microfibrils
(15, 16)? It may be that different mutant fibrillin-1 molecules may
demonstrate different fates, depending upon the location and type of
mutation. In order to address these issues, molecular interactions that
determine how fibrillin-1 assembles into microfibrils must be
understood in more detail.
Preparation of Native Monomeric Fibrillin-1--
Serum-free
medium from normal human skin fibroblasts was collected after a 48-h
incubation period. After concentration by ultrafiltration (Amicon), the
medium was applied to mAb1 26 antibody affinity chromatography, and fibrillin-1 was eluted from the
column with 0.1 M glycine-HCl, pH 2.5. mAb 26 is specific for fibrillin-1 (17). Radioactive fibrillin-1 markers were prepared as
described previously (1).
Extraction of Chick Embryonic Tissue--
The embryos of White
Leghorn chickens were subjected to 5 mg of
Aortae were extracted sequentially with the following reagents: (i)
PBS, (ii) 1 M NaCl in 50 mM Tris-HCl, pH 7.5, (iii) 8 M urea in 50 mM Tris-HCl, pH 7.5 (twice), and (iv) 50 mM dithioerythritol (DTE) in 8 M urea/50 mM Tris-HCl, pH 7.5. All extractions
were performed at 4 °C with the following protease inhibitors
present: 0.001 M N-ethylmaleimide, 0.004 M EDTA, and 0.001 M phenylmethylsulfonyl fluoride. Tissue was dissociated in extraction buffers with a Brinkmann
polytron. Then, extracts were centrifuged at 4 °C for 1 h at
14,000 rpm in a Sorvall RC-5B centrifuge, and supernatants were stored
at Organ Cultures of Chick Aortae--
Aortae from batches of
50-60 embryos at a time were dissected and incubated in Dulbecco's
modified Eagle's medium, without cysteine (sometimes without
methionine as well), in a shaking water bath at 37 °C. In
preliminary experiments, they were radioactively labeled with medium
containing 50 µCi/ml [35S]cysteine (Amersham Pharmacia
Biotech) and 50 µCi/ml [35S]methionine (Amersham
Pharmacia Biotech). In subsequent experiments, [14C]cysteine (NEN Life Science Products) was used at a
concentration of 1-5 µCi/ml of medium. The medium was also
supplemented with 0.02 M HEPES and penicillin-streptomycin
(50 µg/ml and 50 units/ml, respectively) (Life Technologies, Inc.).
The aortae were then chased with medium containing cysteine (and
methionine) and extracted as above. The medium usually contained 64 µg/ml
For immunoaffinity purification of fibrillin present in the 8 M urea extracts, the extracts were dialyzed against 50 mM Tris-HCl, pH 7.5, containing 0.5 M NaCl and
2 M urea, at 4 °C overnight. Almost all of the material
remained in solution after dialysis. Before application to mAb
201/Sepharose, the samples were diluted with cold PBS to a urea
concentration of 0.5 M. After extensive washing of the
column with PBS-0.05% Tween 20, the column was eluted with 0.1 M glycine-HCl, pH 2.5. Fractions were collected, and
radioactivity was determined by scintillation counting.
Expression of Recombinant Polypeptides of Fibrillin-1--
A
recombinant fibrillin-1 expression construct rF24, coding for
Met1 to Ile489 and an additional 60 bp 5' to
the proposed start codon, was prepared using expression construct rF23
(18). To replace the BM-40 signal peptide in rF23 with the sequence for
the putative fibrillin-1 signal peptide, a 1441-bp
NheI-NotI fragment from pCEPSP-rF23H was fused
with the NheI-NotI restricted pCEP4 vector
(Invitrogen), which does not contain a sequence for a signal peptide.
The resulting plasmid was designated pCEP-rF23H. To add the coding
sequence for the putative fibrillin-1 signal peptide and 60 preceding
bp, clone HFBN29 (9) was amplified using primer DR62
(5'-ATAGTTTAGCGGCCGCTAGCCGCAGACCGAGCCCCGGG-3'), which introduced a
NotI and a NheI restriction site at the 5' end,
and primer N1911AS (5'-AATTTCCTCCCTGACAGAGCCC-3'). A 134-bp NotI-NcoI fragment was subcloned into the
NotI-NcoI restricted pBS-HFBN23/29 (4), and the
1478-bp NheI-AgeI fragment was then ligated with
the NheI-AgeI restricted pCEP-rF23H. The
resulting expression plasmid was designated pCEP-rF24H.
To make expression construct rF38, coding for Ser115 to
Glu287, clone HFBN29 was amplified with sense primer DR90
(5'-CGTAGCTAGCATCCATACAACACTGCAATATTCG-3'), introducing a
NheI restriction site at the 5' end, and antisense primer
DR91 (5'-ACCGCTCGAGCTAGTGATGGTGATGGTGATGTTCACATTTTTGTGACACTTC-3'), introducing the sequence for 6 histidine residues, a stop codon, and a
XhoI restriction site at the 3' end. The 547-bp
NheI-XhoI fragment was then subcloned in
pCEP4/
Transfection of 293/EBNA cells (Invitrogen) and selection of clones was
performed as described previously (4). Purification of rF24 and rF38 by
chelating chromatography was as described for construct rF20 (4).
Alternatively, rF24 was purified by affinity chromatography with mAb 26 as described for recombinant fragment rF11 (4). Expression and
purification of the fibrillin-1 recombinant fragment rF31 and the
fibrillin-2 fragments rF33 and rF37 were described previously (17).
Characterization of Recombinant Polypeptides--
Analysis of
the secreted fraction of recombinant rF24 compared with the fraction
retained within the cells was performed by Western blot analysis. 8 ml
of serum-free medium (48-h incubation time) from a confluent 100-mm
cell culture dish was harvested. The cell layer was then washed two
times with PBS and solubilized in 0.2 ml of SDS sample buffer. 1 ml of
TCA-precipitated culture medium and 0.03 ml of the cell fraction were
then analyzed under nonreducing conditions with mAb 26 (~10 µg/ml)
and goat anti-mouse IgG conjugated to horseradish peroxidase (Bio-Rad;
1:800 dilution). Controls included nontransfected 293/EBNA cells and
conditioned medium from these cells.
Electroblotted recombinant peptides were analyzed on an automated
sequencer (Applied Biosystems) using Edman degradation.
Analysis of Free Cysteine Residues--
To determine free
cysteine residues in rF24 and rF38, the polypeptides were solubilized
in 0.5 M Tris-HCl, pH 8.0, 6 M guanidine, 2 mM EDTA and derivatized with a 10-fold molar excess (over
cysteine residues) of iodoacetamide under N2 at 37 °C
for 30 min in the dark. The polypeptides were desalted by reverse-phase
chromatography (C18, Vydac 218TP52), lyophilized, and
reduced with a 10-fold molar excess (over cysteine residues) of
dithiothreitol under N2 at 37 °C for 2 h in the
dark. The fragments were then derivatized with a 4-fold molar excess
(over dithiothreitol) of 4-vinylpyridine at 25 °C for 90 min in the
dark. The reduced and alkylated peptides were then again desalted by
C18 reverse-phase chromatography and either submitted
directly to Edman degradation (rF24) or digested with endoproteinase
Glu-C (Roche Molecular Biochemicals) (rF38) in 25 mM
ammonium acetate, pH 4.0, at 25 °C for 24 h. Endo-Glu-C peptides of rF38 were separated by C18 reverse-phase
chromatography and then analyzed by Edman degradation. N-terminal
sequences of rF24 or proteolytic peptides of rF38 were determined by
automated protein sequencing (Hewlett Packard G1000S). Free cysteine
residues were identified as amidomethyl cysteine, and disulfide-bonded cysteine residues were identified as pyridylethyl cysteines.
To determine whether free cysteines are located on the surface of
molecules, recombinant polypeptides of fibrillin-1 (rF31 and rF38) and
fibrillin-2 (rF33 and rF37) were derivatized with 5,5-dithiobis-(2-nitrobenzoate) (DTNB) (Ellman's reagent; Fluka). The
reaction was carried out in 50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM CaCl2, 1.875 mM DTNB in the presence or absence of 6 M
guanidine-HCl at 20 °C. Recombinant polypeptides were added to
freshly prepared reaction buffer at final concentrations of 10.1 (rF31), 14.5 (rF33), 12.0 (rF37), and 9.3 µM (rF38).
Because the concentration of DTNB is much higher (130-200-fold) than
the concentration of free cysteine residues, the reaction can be
considered of pseudo-first order: protein-S Fibroblasts Secrete Fibrillin-1 Monomers into the
Medium--
Previous identification and characterization of native
fibrillin-1 was accomplished using monoclonal antibodies specific for fibrillin-1 (1, 5, 17). Direct evidence that immunoisolated molecules
synthesized and secreted by human fibroblasts are fibrillin-1 monomers
has been obtained by N-terminal sequence analysis (data not shown). The
authentic fibrillin-1 N terminus (45RGGGG(H)DALKGPNVXG)
begins after a furin-type cleavage site in profibrillin-1
(41RAKR), which was predicted to be utilized in studies
employing recombinant fibrillin-1 polypeptides (4).
In Organ Cultures, Fibrillin-1 Is Rapidly Assembled into
Disulfide-linked Multimers--
In contrast to monomeric molecules,
which can be obtained from the medium of cells in culture, the tissue
form of fibrillin-1 is polymeric. After fibrillin-1 assembles into a
microfibril, it is cross-linked and is very difficult to solubilize. In
order to determine initial steps in the process by which fibrillin-1 becomes cross-linked and insoluble, pulse-chase and extraction studies
were performed using radiolabeled organ cultures of
aortae.2
Fig. 2 demonstrates that newly
synthesized radiolabeled fibrillin can be extracted sequentially from
the tissue, using progressively harsher denaturing conditions. A
soluble pool containing fibrillin can be removed using PBS (Fig. 2,
lane 2). Even after a 1 M NaCl extraction
(lane 3), a pool that can only be solubilized with 8 M urea remains (lane 4). After a second
extraction with 8 M urea (lane 5), an insoluble
pool can be selectively extracted with disulfide-bond reducing agents
(lane 6). The band labeled as fibrillin (Fb) was
confirmed by immunoblotting (data not shown).
After exhaustive prior extraction, chick aortae contained one major
[14C]cysteine-labeled band, fibrillin, which could be
extracted with DTE. Pulse-chase experiments were conducted in order to
determine whether the formation of intermolecular disulfide cross-links enables fibrillin to become increasingly insoluble with time. Fig.
3 shows the results of one representative
pulse-chase experiment. Organ cultures of aortae were pulsed for 30 min
and chased for 0-19 h. Aortae from each chase time point were
extracted sequentially with PBS, 1 M NaCl, 8 M
urea, 8 M urea, and 50 mM DTE. After 30 min of
labeling (0 h chase), newly synthesized fibrillin was present in the
PBS and 8 M urea extracts (Fig. 3, lanes 1 and
5) but was not present in the DTE extract (lane
13). After 1 h of chase, fibrillin was found in all extracts
(lanes 2, 6, and 10), including the DTE extract
(lane 14). After 3 h of chase, fibrillin was decreased in the PBS (lane 3) and 8 M urea (lanes
7 and 11) extracts and increased in the DTE extract
(lane 15). After 19 h, the PBS extract no longer
contained appreciable amounts of fibrillin (lane 4), and 8 M urea extracts contained smaller amounts of fibrillin
(lanes 8 and 12) than at 1 and 3 h of chase.
Most of the radioactively labeled fibrillin present at 19 h of
chase was resistant to prior extractions and was solubilized by DTE
(lane 16: compare this lane with lanes 4, 8, and
12). Because the 1 M NaCl extracts contained very little fibrillin, they are not shown here.
Electrophoresis and molecular sieve chromatography demonstrated that
PBS extracts of aortae after 0-4 h of chase contained monomers, not
multimers, whereas 8 M urea extracts of aortae after 4 h of chase contained multimers and small amounts of monomer (data not
shown). The 8 M urea extract of pulsed (1 h) and chased (4 h) aortae was diluted with PBS and applied to an antibody affinity column. Most of the fibrillin, eluted from the column, failed to enter
the stacking gel when the sample was run without reducing agent (Fig.
4a, lane 1). A small amount of
fibrillin monomer was present (arrow). When the sample was
reduced (Fig. 4a, lane 2), the immunoisolated material was
composed primarily of fibrillin and additional species, which might
represent nonreducibly cross-linked fibrillin molecules, degradation
products of microfibrils, or contaminants of the immunoprecipitation
(including potential fibrillin-binding proteins). When this
immunoisolated fibrillin aggregate was run on a 1.5% agarose gel and
compared with mouse type IV procollagen markers, the minimum molecular
mass calculated for the fibrillin aggregate was greater than 8 million
Da (Fig. 4b).
Determination of Free Cysteine Residues--
Fibrillin-1 is
composed of 282 cysteine residues in 47 epidermal growth factor-like
repeats, 56 cysteine residues in seven 8-cysteine repeats, 17 cysteine
residues in two hybrid repeats, 4 cysteine residues in the N terminus,
and 2 cysteine residues in the C terminus (9). Two recombinant
polypeptides, rF24 and rF38 (Fig. 1), were produced in order to examine
the cysteine residues present in the N terminus and in the first hybrid
repeat, which contains nine cysteine residues. Sufficient quantities of a C-terminal recombinant polypeptide, rF8 (22), could not be produced
for these studies.
For rF24, stably transfected 293/EBNA cells and serum-free medium were
analyzed by Western blotting with mAb 26, specific for fibrillin-1
(17). The majority (>95%) of the 50-kDa rF24 polypeptide was secreted
into the medium, demonstrating that the putative signal sequence
starting at Met1 (10) is functional (data not shown).
Immunoblotting and affinity chromatography with mAb 26 indicated
correct folding of rF24, because binding of mAb 26 to fibrillin-1
relies on proper formation of disulfide bonds (4). rF24 was purified to
homogeneity by affinity chromatography on mAb 26 (Fig.
5). Edman degradation of the major band
resulted in two N-terminal sequences, 25ADANLEAGNVKE and
45RGGGGHDALKGP, in approximately equal amounts. This
demonstrates that the fibrillin-1 signal sequence is cleaved between
Gly24 and Ala25 and that rF24 is also
processed, like authentic fibrillin-1, after the furin-type cleavage
sequence. Edman degradation of the minor band gave a single fibrillin-1
sequence, 115SIQHXNIRXMNG. This sequence begins after the
first epidermal growth factor-like repeat in fibrillin-1, indicating a
protease-sensitive site. rF24 was used to determine the free
sulfhydryls in the unique N-terminal end. To determine free sulfhydryls
in the first hybrid motif, a smaller recombinant fragment, rF38, was
used. SDS-PAGE of purified rF38 demonstrated the expected molecular
mass of 20 kDa and a reducible dimer of 40 kDa (Fig.
6).
rF24 and rF38 were alkylated by iodoacetamide and then reduced and
again alkylated with 4-vinylpyridine, resulting in amidomethyl cysteine
residues for free sulfhydryl groups and pyridylethyl cysteine if the
cysteine residue was originally involved in a disulfide bond. To
promote accessibility to the alkylating agents, these reactions were
performed in the presence of 6 M guanidine. All four
cysteine residues of the unique N-terminal domain were modified with
4-vinylpyridine, demonstrating that they all were involved in disulfide
bonds. Only the third cysteine (Cys204) in the first hybrid
repeat was modified with iodoacetamide, whereas the other 8 cysteine
residues within this motif were modified with 4-vinylpyridine. This
demonstrates that Cys204, the nonconserved cysteine within
this motif (Table I), occurs as a free
thiol in rF38.
In order to determine whether the free cysteine residue is located on
the surface of molecules and readily available for intermolecular disulfide bond formation, the fibrillin-1 recombinant fragments rF31
and rF38 and the fibrillin-2 recombinant fragments rF33 and rF37 were
reacted with 5,5'-dithiobis-(2-nitrobenzoate) either in a physiological
buffer (TBS) or in a denaturing buffer (6 M guanidine). For
rF38, virtually identical total numbers of free cysteine residues per
molecule protein were observed in TBS buffer (0.93 ± 0.003 S.D.)
and in guanidine buffer (0.91 ± 0.002 S.D.) (Fig.
7a), demonstrating that the
free cysteine residue is exposed at the surface of the molecule. The
reaction was somewhat faster in guanidine buffer (rate constant of
k = 1.34 ± 0.01 S.D.) compared with the reaction
in physiological buffer (k = 0.33 ± 0.005 S.D.), indicating that the free cysteine residue is somewhat more favorably available to DTNB under denaturing conditions. Similar results were
obtained for the fibrillin-2 recombinant fragment rF37. In TBS buffer,
0.81 ± 0.007 S.D. free cysteine residues per molecule were
obtained, compared with 0.94 ± 0.002 S.D. in guanidine buffer (Fig. 7b). The control polypeptides rF31 and rF33 displayed
no evidence of free cysteine residues.
Here, evidence is presented that indicates that
intermolecular disulfide bond formation is the first step in fibrillin
multimerization and microfibril assembly. In organ-cultured
tissues, pulse-chase experiments demonstrate that intermolecular
disulfide bond formation occurs within the first few hours after
synthesis and secretion of the monomeric fibrillin molecule. Data
presented here show that formation of intermolecular disulfide bonds
coincides with progressive resistance of fibrillin to extraction.
Selective final extraction with a reducing agent suggests that
fibrillin is the only cysteine-rich high molecular weight
microfibrillar component that is cross-linked and stabilized in this
manner (Fig. 2).
Recombinant fibrillin polypeptides were produced in order to determine
the location and number of free cysteine residues that could
potentially be involved in the formation of intermolecular disulfide
bonds. Using an approach that previously resulted in properly folded
and well characterized recombinant fibrillin polypeptides (4, 17, 18),
N-terminal polypeptides rF24 and rF38 were produced and characterized
here. Sequence analysis demonstrated that all four cysteine residues
present in the fibrillin-1 N terminus were held in intrachain disulfide
bonds. Because these four cysteine residues are conserved in the
N-terminal region of fibrillin-2, it is likely that they also form
intrachain disulfide bonds in fibrillin-2. A single cysteine residue
was free in rF38 and was identified as the nonconserved cysteine
residue (Cys204) present in the first hybrid domain of
fibrillin-1. Evidence was presented to demonstrate that this free
cysteine residue is available on the surface of the molecule for
intermolecular disulfide bond formation.
In addition, reaction with Ellman's reagent suggested that a large
recombinant polypeptide of fibrillin-2, rF37, contained one free
cysteine residue, whereas control fragments, rF31 (fibrillin-1) and
rF33 (fibrillin-2), which are composed of all major types of domains
present in fibrillins, did not react with DTNB. By comparison with
results obtained for rF38 and with sequence homologies (Table I), it is
likely that the free cysteine residue present in rF37 is the
nonconserved cysteine residue present in the first hybrid domain.
The family of latent transforming growth factor- Sequence analysis of rF24 allowed the determination of the fibrillin-1
signal peptide cleavage site, just before the sequence 25ADANLEAGNVKE. This finding agrees with recently published
results using recombinant fibrillin-1 fragments expressed in an
alternative expression system (30). In addition, utilization of a
processing site after a consensus furin-type cleavage signal was
demonstrated by N-terminal sequence analysis of rF24 as well as
authentic fibrillin-1 from fibroblast medium.
In summary, the data presented suggest that the initial steps in the
polymerization and stabilization of fibrillin-1 monomers into
microfibrils involves the formation of intermolecular disulfide bonds.
These intermolecular disulfide bonds may cross-link fibrillin monomers
to other cross-linked fibrillin molecules or to high molecular weight
undetermined species (Fig. 4a, lane 2). The nonconserved cysteine (Cys204) present in the first hybrid domain is an
available site for the formation of these important intermolecular
disulfide bonds.
Noe L. Charbonneau is gratefully acknowledged
for help with the figures and for computer graphics.
*
This work was supported by grants from the Shriners
Hospitals for Children (to L. Y. S. and H. P. B.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
¶
To whom correspondence should be addressed: Shriners Hospital
for Children, 3101 S.W. Sam Jackson Park Rd., Portland, OR 97201. Tel.: 503-221-3436; Fax: 503-221-3451; E-mail: lys@shcc.org.
2
A version of these organ culture studies was
previously published as unreviewed proceedings of a meeting (21).
The abbreviations used are:
mAb, monoclonal
antibody;
PBS, phosphate-buffered saline;
DTE, dithioerythritol;
DTNB, 5,5-dithiobis-(2-nitrobenzoate);
TBS, Tris-buffered saline;
LTBP, latent transforming growth factor-
Initial Steps in Assembly of Microfibrils
FORMATION OF DISULFIDE-CROSS-LINKED MULTIMERS CONTAINING
FIBRILLIN-1*
,
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (26K):
[in a new window]
Fig. 1.
Schematic drawing of recombinant polypeptides
of fibrillin-1 and fibrillin-2 used in this study. rF24 and rF38 are
described here. rF31, rF33, and rF37 were previously described
elsewhere (17).
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-aminopropionitrile in
phosphate-buffered saline (PBS), pH 7.4, injected into the air sack on
day 14. Embryos were sacrificed on day 17, and aortae were dissected
and placed either in liquid N2 or in organ culture medium
(see below).
90 °C. Pellets were then extracted with the next buffer, using
the polytron, and centrifuged. The second 8 M urea extraction went overnight at 4 °C. All chemicals were from Sigma.
-aminopropionitrile, unless otherwise specified. For each
experiment, equal numbers of aortae were removed at specified time
points and immediately frozen in liquid N2.
III4 (19). The resulting plasmid was designated
pCEPSP-rF38.
+ DTNB
protein-S-D + TNB
. The absorbance (at 412 nm) was
measured over time (25 min). The concentration of free cysteine
residues was equivalent to the concentration of TNB
,
calculated from the molar extinction coefficient of the
TNB
,
= 13,600 M (20). The following
equation was used for curve fitting: [TNB
] = [protein-SH]0 × (1
e
kt), where [TNB
] = concentration of the TNB anion, [protein-SH]0 = concentration (M) of free thiols in the protein at time 0, t = time (min), and k = rate constant
of the reaction (min
1).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (78K):
[in a new window]
Fig. 2.
SDS-PAGE (3-5% polyacrylamide gradient) of
[14C]cysteine-labeled proteins extracted from chick
aortae that had been continuously pulsed for 17 h. Lane
1, fibrillin marker immunoisolated from the medium of human
fibroblasts in culture; lane 2, PBS extract; lane
3, 1 M NaCl extract; lane 4, 8 M urea extract; lane 5, second 8 M
urea extract; lane 6, DTE extract. Single arrow
marks the top of the stacking gel; double arrow indicates
the beginning of the running gel. Prior to electrophoresis, all samples
were treated with reducing agent. Fb denotes the position of
monomeric fibrillin-1.

View larger version (120K):
[in a new window]
Fig. 3.
SDS-PAGE (3-5% polyacrylamide gradient) of
[14C]cysteine-labeled (pulsed for 30 min) proteins
extracted from equal numbers of chick aortae after different periods of
chase. Equal volumes of extract were applied to each channel.
Lanes 1-4, PBS extracts after 0 min (lane 1),
1 h (lane 2), 3 h (lane 3), and 19 h (lane 4) of chase. Lanes 5-8, 8 M
urea extracts after 0 min (lane 5), 1 h (lane
6), 3 h (lane 7), and 19 h (lane
8) of chase. Lanes 9-12, second 8 M urea
extracts after 0 min (lane 9), 1 h (lane
10), 3 h (lane 11), and 19 h (lane
12) of chase. Lanes 13-16, DTE extracts after 0 min
(lane 13), 1 h (lane 14), 3 h
(lane 15), and 19 h (lane 16) of chase. All
samples were treated with reducing agent prior to electrophoresis. The
position of fibrillin (Fb) is marked with an
arrow.

View larger version (51K):
[in a new window]
Fig. 4.
a. SDS-PAGE (3-5% polyacrylamide gradient) of
immunoprecipitated fibrillin from 8 M urea extracts of
chick aortae pulsed for 1 h with 250 µCi/ml
[35S]cysteine and chased for 5 h. Lane 1, nonreduced (
) (without
-mercaptoethanol) fibrillin-1
immunoprecipitate; unlabeled arrow indicates the presence of
small amounts of monomeric fibrillin-1. Lane 2, reduced (+)
(with
-mercaptoethanol) fibrillin-1 immunoprecipitate. Lane
3, reduced (+) (with
-mercaptoethanol) fibrillin-1
(Fb) and fibronectin (Fn) markers from human
fibroblast medium. b, 1.5% agarose gel of
immunoprecipitated nonreduced fibrillin-1 (lane 1) shown in
a, lane 1. The arrow indicates the position of
the fibrillin-1 monomer. Lanes 2 and 3, nonreduced type IV collagen markers, with estimated molecular masses of
0.54 (monomer), 1.08 (dimer), 1.62 (trimer), and 2.16 (tetramer)
million Da.

View larger version (19K):
[in a new window]
Fig. 5.
Identification of the signal peptide cleavage
site and proteolytic processing sites in fibrillin-1. Recombinant
fragment rF24 was purified by immunoaffinity chromatography using mAb
26. The purified material was subjected to SDS gel electrophoresis
(shown here). Individual bands from the same fraction were analyzed by
N-terminal sequencing after blotting onto membranes. The sequences are
indicated. The positions of globular marker proteins (M) are
indicated in kDa.

View larger version (60K):
[in a new window]
Fig. 6.
Characterization of purified recombinant
polypeptide rF38 by SDS gel electrophoresis. Purified rF38 was
analyzed either nonreduced (NR) or after reduction with 20 mM dithiothreitol (R). Note that the nonreduced
material contains reducible dimers of 40 kDa. The monomer has an
apparent molecular mass of 20 kDa. The positions of globular marker
proteins are indicated at the left in kDa.

View larger version (25K):
[in a new window]
Fig. 7.
Demonstration of surface accessibility of
free cysteine residues in fibrillin-1 and fibrillin-2. Recombinant
fibrillin-1 fragments rF38 (
and
) and rF31 (
and
)
(a) or fibrillin-2 fragments rF37 (
and
) and rF33
(
and
) (b) were reacted with Ellman's reagent either
in a physiological buffer, TBS (closed symbols), or in a
denaturing buffer containing 6 M guanidine-HCl (open
symbols). The amount of free thiols (mol/mol of protein) was
calculated from the absorbance at 412 nm as described under
"Experimental Procedures."
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
-binding proteins
(LTBP-1, -2, -3, and -4) (23-26) resembles fibrillins, except that the
LTBPs have variable lengths and are smaller than the fibrillins. LTBP-1
has been immunolocalized to microfibrils (27-29). The LTBPs are
composed of the same domains present in fibrillins, including one
hybrid domain. However, the single hybrid domain in LTBPs, like the
second hybrid domain in fibrillins, does not contain the extra cysteine
residue (Table I).
![]()
ACKNOWLEDGEMENT
![]()
FOOTNOTES
Present Address: Dept. of Medical Molecular Biology, University of
Lübeck, D-23562 Lübeck, Germany.
![]()
ABBREVIATIONS
-binding protein;
bp, base pair(s).
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
1.
Sakai, L. Y.,
Keene, D. R.,
and Engvall, E.
(1986)
J. Cell Biol.
103,
2499-2509 2.
Keene, D. R.,
Maddox, B. K.,
Kuo, H. J.,
Sakai, L. Y.,
and Glanville, R. W.
(1991)
J. Histochem. Cytochem.
39,
441-449[Abstract]
3.
Sakai, L. Y.,
and Keene, D. R.
(1994)
Methods Enzymol.
245,
29-52[Medline]
[Order article via Infotrieve]
4.
Reinhardt, D. P.,
Keene, D. R.,
Corson, G. M.,
Gambee, J. E.,
Pöschl, E.,
and Sakai, L. Y.
(1996)
J. Mol. Biol.
258,
104-116[CrossRef][Medline]
[Order article via Infotrieve]
5.
Sakai, L. Y.,
Keene, D. R.,
Glanville, R. W.,
and Bächinger, H. P.
(1991)
J. Biol. Chem.
266,
14763-14770 6.
Downing, A. K.,
Knott, V.,
Werner, J. M.,
Cardy, C. M.,
Campbell, I. D.,
and Handford, P. A.
(1996)
Cell
85,
597-605[CrossRef][Medline]
[Order article via Infotrieve]
7.
Ross, R.,
and Bornstein, P.
(1969)
J. Cell Biol.
40,
366-381 8.
Maslen, C. L.,
Corson, G. M.,
Maddox, B. K.,
Glanville, R. W.,
and Sakai, L. Y.
(1991)
Nature
352,
334-337[CrossRef][Medline]
[Order article via Infotrieve]
9.
Corson, G. M.,
Chalberg, S. C.,
Dietz, H. C.,
Charbonneau, N. L.,
and Sakai, L. Y.
(1993)
Genomics
17,
476-484[CrossRef][Medline]
[Order article via Infotrieve]
10.
Pereira, L.,
D'Alessio, M.,
Ramirez, F.,
Lynch, J. R.,
Sykes, B.,
Pangilinan, T.,
and Bonadio, J.
(1993)
Hum. Mol. Genet.
2,
961-968 11.
Yuan, X.,
Downing, A. K.,
Knott, V.,
and Handford, P. A.
(1997)
EMBO J.
16,
6659-6666[CrossRef][Medline]
[Order article via Infotrieve]
12.
Collod-Beroud, G.,
Beroud, C.,
Ades, L.,
Black, C.,
Boxer, M.,
Brock, D. J. H.,
Holman, K. J.,
de Paepe, A.,
Francke, U.,
Grau, U.,
Hayward, C.,
Klein, H.-G.,
Liu, W.,
Nuytinck, L.,
Peltonen, L.,
Perez, A. B. A.,
Rantamäki, T.,
Junien, C.,
and Boileau, C.
(1998)
Nucleic Acids Res.
26,
229-233 13.
Liu, W.-O.,
Oefner, P. J.,
Qian, C.,
Odom, R. S.,
and Francke, U.
(1998)
Genet. Testing
1,
237-242[Medline]
[Order article via Infotrieve]
14.
Reinhardt, D. P.,
Ono, R. N.,
and Sakai, L. Y.
(1997)
J. Biol. Chem.
272,
1231-1236 15.
Dzamba, B. J.,
Charbonneau, N. L.,
Keene, D. R.,
and Sakai, L. Y.
(1998)
in
Extracellular Matrix-Cellular Interactions: Molecules to Diseases
(Ninomiya, Y., B. R.
, Olsen
, and Ooyama, T., eds)
, pp. 23-40, Japan Scientific Societies Press, Tokyo
16.
Dietz, H. C.,
McIntosh, I.,
Sakai, L. Y.,
Corson, G. M.,
Chalberg, S. C.,
Pyeritz, R. E.,
and Francomano, C. A.
(1993)
Genomics
17,
468-475[CrossRef][Medline]
[Order article via Infotrieve]
17.
Keene, D. R.,
Jordan, C. D.,
Reinhardt, D. P.,
Ridgway, C. C.,
Ono, R. N.,
Corson, G. M.,
Fairhurst, M.,
Sussman, M. D.,
Memoli, V. A.,
and Sakai, L. Y.
(1997)
J. Histochem. Cytochem.
45,
1069-1082 18.
Reinhardt, D. P.,
Sasaki, T.,
Dzamba, B. J.,
Keene, D. R.,
Chu, M.-L.,
Göhring, W.,
Timpl, R.,
and Sakai, L. Y.
(1996)
J. Biol. Chem.
271,
19489-19496 19.
Mayer, U.,
Pöschl, E.,
Gerecke, D. R.,
Wagman, D. W.,
Burgeson, R. E.,
and Timpl, R.
(1995)
FEBS Lett.
365,
129-132[CrossRef][Medline]
[Order article via Infotrieve]
20.
Ellman, G. L.
(1959)
Arch. Biochem. Biophys.
82,
70-77[CrossRef][Medline]
[Order article via Infotrieve]
21.
Sakai, L. Y.
(1990)
in
Elastin: Chemical and Biological Aspects
(Tamburro, A.
, and Davidson, J., eds)
, pp. 213-227, Congedo Editore, Galatina, Italy
22.
Lönnqvist, L.,
Reinhardt, D.,
Sakai, L.,
and Peltonen, L.
(1998)
Hum. Mol. Genet.
7,
2039-2044 23.
Kanzaki, T.,
Olofsson, A.,
Moren, A.,
Wernstedt, C.,
Hellman, U.,
Miyazono, K.,
Claesson-Welsh, L.,
and Heldin, C. H.
(1990)
Cell
61,
1051-1061[CrossRef][Medline]
[Order article via Infotrieve]
24.
Moren, A.,
Olofsson, A.,
Stenman, G.,
Sahlin, P.,
Kanzaki, T.,
Claesson-Welsh, L.,
ten Dijke, P.,
Miyazono, K.,
and Heldin, C.-H.
(1994)
J. Biol. Chem.
269,
32469-32478 25.
Yin, W.,
Smiley, E.,
Germiller, J.,
Mecham, R. P.,
Florer, J. B.,
Wenstrup, R. J.,
and Bonadio, J.
(1995)
J. Biol. Chem.
270,
10147-10160 26.
Saharinen, J.,
Taipale, J.,
Monni, O.,
and Keski-Oja, J.
(1998)
J. Biol. Chem.
273,
18459-18469 27.
Taipale, J.,
Saharinen, J.,
Hedman, K.,
and Keski-Oja, J.
(1996)
J. Histochem. Cytochem.
44,
875-889[Abstract]
28.
Nakajima, Y.,
Miyazono, K.,
Kato, M.,
Takase, M.,
Yamagishi, T.,
and Nakamura, H.
(1997)
J. Cell Biol.
136,
193-204 29.
Dallas, S. L., Keene, D. R., Bruder, S. P., Saharinen,
J., Sakai, L. Y., Mundy, G. R., and Bonewald, L. F. (2000) J. Bone Min. Res., in press
30.
Ritty, T. M.,
Broekelmann, T.,
Tisdale, C.,
Milewicz, D. M.,
and Mecham, R. P.
(1999)
J. Biol. Chem.
274,
8933-8940
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
G. Sengle, N. L. Charbonneau, R. N. Ono, T. Sasaki, J. Alvarez, D. R. Keene, H. P. Bachinger, and L. Y. Sakai Targeting of Bone Morphogenetic Protein Growth Factor Complexes to Fibrillin J. Biol. Chem., May 16, 2008; 283(20): 13874 - 13888. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hubmacher, E. I. El-Hallous, V. Nelea, M. T. Kaartinen, E. R. Lee, and D. P. Reinhardt Biogenesis of extracellular microfibrils: Multimerization of the fibrillin-1 C terminus into bead-like structures enables self-assembly PNAS, May 6, 2008; 105(18): 6548 - 6553. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. El-Hallous, T. Sasaki, D. Hubmacher, M. Getie, K. Tiedemann, J. Brinckmann, B. Batge, E. C. Davis, and D. P. Reinhardt Fibrillin-1 Interactions with Fibulins Depend on the First Hybrid Domain and Provide an Adaptor Function to Tropoelastin J. Biol. Chem., March 23, 2007; 282(12): 8935 - 8946. [Abstract] [Full Text] [PDF] |
||||
![]() |
C.-L. Kuo, Z. Isogai, D. R. Keene, N. Hazeki, R. N. Ono, G. Sengle, H. Peter Bachinger, and L. Y. Sakai Effects of Fibrillin-1 Degradation on Microfibril Ultrastructure J. Biol. Chem., February 9, 2007; 282(6): 4007 - 4020. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Chaudhry, S. A. Cain, A. Morgan, S. L. Dallas, C. A. Shuttleworth, and C. M. Kielty Fibrillin-1 regulates the bioavailability of TGF{beta}1 J. Cell Biol., January 29, 2007; 176(3): 355 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
P N Robinson, E Arteaga-Solis, C Baldock, G Collod-Beroud, P Booms, A De Paepe, H C Dietz, G Guo, P A Handford, D P Judge, et al. The molecular genetics of Marfan syndrome and related disorders J. Med. Genet., October 1, 2006; 43(10): 769 - 787. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Baldock, V. Siegler, D. V. Bax, S. A. Cain, K. T. Mellody, A. Marson, J. L. Haston, R. Berry, M.-C. Wang, J. G. Grossmann, et al. Nanostructure of fibrillin-1 reveals compact conformation of EGF arrays and mechanism for extensibility PNAS, August 8, 2006; 103(32): 11922 - 11927. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hubmacher, K. Tiedemann, R. Bartels, J. Brinckmann, T. Vollbrandt, B. Batge, H. Notbohm, and D. P. Reinhardt Modification of the Structure and Function of Fibrillin-1 by Homocysteine Suggests a Potential Pathogenetic Mechanism in Homocystinuria J. Biol. Chem., October 14, 2005; 280(41): 34946 - 34955. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. A. Cain, C. Baldock, J. Gallagher, A. Morgan, D. V. Bax, A. S. Weiss, C. A. Shuttleworth, and C. M. Kielty Fibrillin-1 Interactions with Heparin: IMPLICATIONS FOR MICROFIBRIL AND ELASTIC FIBER ASSEMBLY J. Biol. Chem., August 26, 2005; 280(34): 30526 - 30537. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marson, M. J. Rock, S. A. Cain, L. J. Freeman, A. Morgan, K. Mellody, C. A. Shuttleworth, C. Baldock, and C. M. Kielty Homotypic Fibrillin-1 Interactions in Microfibril Assembly J. Biol. Chem., February 11, 2005; 280(6): 5013 - 5021. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Rock, S. A. Cain, L. J. Freeman, A. Morgan, K. Mellody, A. Marson, C. A. Shuttleworth, A. S. Weiss, and C. M. Kielty Molecular Basis of Elastic Fiber Formation: CRITICAL INTERACTIONS AND A TROPOELASTIN-FIBRILLIN-1 CROSS-LINK J. Biol. Chem., May 28, 2004; 279(22): 23748 - 23758. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. L. Charbonneau, B. J. Dzamba, R. N. Ono, D. R. Keene, G. M. Corson, D. P. Reinhardt, and L. Y. Sakai Fibrillins Can Co-assemble in Fibrils, but Fibrillin Fibril Composition Displays Cell-specific Differences J. Biol. Chem., January 17, 2003; 278(4): 2740 - 2749. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Isogai, R. N. Ono, S. Ushiro, D. R. Keene, Y. Chen, R. Mazzieri, N. L. Charbonneau, D. P. Reinhardt, D. B. Rifkin, and L. Y. Sakai Latent Transforming Growth Factor beta -binding Protein 1 Interacts with Fibrillin and Is a Microfibril-associated Protein J. Biol. Chem., January 17, 2003; 278(4): 2750 - 2757. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lin, K. Tiedemann, T. Vollbrandt, H. Peters, B. Batge, J. Brinckmann, and D. P. Reinhardt Homo- and Heterotypic Fibrillin-1 and -2 Interactions Constitute the Basis for the Assembly of Microfibrils J. Biol. Chem., December 20, 2002; 277(52): 50795 - 50804. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Penner, M. J. Rock, C. M. Kielty, and J. M. Shipley Microfibril-associated Glycoprotein-2 Interacts with Fibrillin-1 and Fibrillin-2 Suggesting a Role for MAGP-2 in Elastic Fiber Assembly J. Biol. Chem., September 13, 2002; 277(38): 35044 - 35049. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. H. Hill, R. Mecham, and B. Starcher Fibrillin-2 Defects Impair Elastic Fiber Assembly in a Homocystei |